UNITE4TB: a new consortium for clinical drug and regimen development for TB

After decades of limited progress, the development of novel anti-TB medicines was revitalised at the start of the 21st century through new initiatives and investments. This has resulted in innovations in treatment regimens thanks to new compounds becoming available and the re-purposing of existing drugs. However, progress has been relatively slow for a disease that, until the emergence of the COVID-19 pandemic, has remained the top infectious killer worldwide. Accelerated action is therefore necessary to reach the ambitious target of “ending TB” set by the WHO within its new Global Strategy (2016–2030).

We are now at the start of a new era. With financial support from the Innovative Medicine Initiative (IMI) in Europe and the German Federal Ministry of Research and Education (BmBF), the UNITE4TB Consortium will begin work in 2021. With a total budget of 185 million euros, 22 European academic institutions, 3 research institutions from the United States and South Africa, 2 European Federation of Pharmaceutical Industries and Association (EFPIA) members and 2 Associated Partners (APs) from Germany, this will be the largest collaboration on clinical TB drug development in the history of the European Union. Over the next 7 years, the Consortium will engage with up to 40 potential trial sites across the globe (including Europe, Asia, Africa and South America) to deliver innovative Phase 2 clinical trials that aim to speed the passage of new anti-TB drugs and regimens to definitive Phase 3 trials and regulatory approval.

The increasing clinical and public health challenge of multidrug-resistant TB (MDR-TB i.e., TB with resistance to at least the two best first-line drugs, rifampicin and isoniazid) has triggered renewed scientific activity in anti-TB drug development. In 2014, the European Medicines Agency (EMA) gave conditional marketing authorisations for pioneer compounds in two novel classes of anti-TB drugs, bedaquiline1 and delamanid.2 In 2020, the EMA3 and US Food and Drug Administration (FDA)4 approved the first-ever, all-oral BPaL regimen for extensively drug-resistant TB (XDR-TB) and treatment-intolerant and failing MDR-TB. However, a more integrated approach to anti-TB drug development is essential, leveraging investments in both preclinical and clinical research capacity and de-risking Phase 3 clinical trials.5 Historically, to gain marketing approval for anti-TB drugs, large and expensive Phase 3 clinical trials have been required to demonstrate efficacy and safety of a new drug, or a new combination regimen, based on results from Phase 2 clinical trials. However, their success has been inconsistent, as exemplified by the fluoroquinolone trials (RemoxTB,6 RIFAQUIN7 and OFLOTUB8), and the partial disconnect between the results of the delamanid Phase 2 and Phase 3 trials.9 The success of the 4-month rifapentine-moxifloxacin regimen is a source of hope for TB regimen development,10 but it comes 21 years after the initial licensure of rifapentine by the US FDA.11 In 2018, a technical consultation organised by the WHO Global TB Programme acknowledged the limits of this traditional pathway and of the traditional endpoints used in Phase 2 trials to predict relapse-free cure with accuracy.12 It made a strong case for new approaches in TB treatment development using innovative Phase 2 and Phase 3 trial designs, relying on novel biomarkers and revised endpoints to assess in a shorter and more streamlined way new combinations of anti-TB drugs to be tested in pivotal trials.13

The UNITE4TB Consortium will address the major challenge of defining new anti-TB drugs and regimens for the 21st century. The consortium will create a platform for conducting innovative Phase 2A, and Phase 2B/C clinical trials that aim to speed the passage of new anti-TB drugs and regimens to definitive Phase 3 trials and regulatory approval.

The increasing clinical and public health challenge of multidrug-resistant TB (MDR-TB i.e., TB with resistance to at least the two best first-line drugs, rifampicin and isoniazid) has triggered renewed scientific activity in anti-TB drug development. In 2014, the European Medicines Agency (EMA) gave conditional marketing authorisations for pioneer compounds in two novel classes of anti-TB drugs, bedaquiline1 and delamanid.2 In 2020, the EMA3 and US Food and Drug Administration (FDA)4 approved the first-ever, all-oral BPaL regimen for extensively drug-resistant TB (XDR-TB) and treatment-intolerant and failing MDR-TB. However, a more integrated approach to anti-TB drug development is essential, facilitating collaborative critical paths for new combination regimens for TB, while simultaneously leveraging investments in both preclinical and clinical research capacity and de-risking Phase 3 clinical trials.5 Historically, to gain marketing approval for anti-TB drugs, large and expensive Phase 3 clinical trials have been required to demonstrate efficacy and safety of a new drug, or a new combination regimen, based on results from Phase 2 clinical trials. However, their success has been inconsistent, as exemplified by the fluoroquinolone trials (RemoxTB,6 RIFAQUIN7 and OFLOTUB8), and the partial disconnect between the results of the delamanid Phase 2 and Phase 3 trials.9 The success of the 4-month rifapentine-moxifloxacin regimen is a source of hope for TB regimen development,10 but it comes 21 years after the initial licensure of rifapentine by the US FDA.11 In 2018, a technical consultation organised by the WHO Global TB Programme acknowledged the limits of this traditional pathway and of the traditional endpoints used in Phase 2 trials to predict relapse-free cure with accuracy.12 It made a strong case for new approaches in TB treatment development using innovative Phase 2 and Phase 3 trial designs, relying on novel biomarkers and revised endpoints to assess in a shorter and more streamlined way new combinations of anti-TB drugs to be tested in pivotal trials.13
to succeed in Phase 3 trials is failing. If we continue with current trial designs and endpoints, generally focused on the development of single drugs rather than regimens, it is estimated it will take 15–20 years to develop a new regimen of 3–4 drugs to treat TB. Given the scale of the TB public health problem, this is unacceptable. New approaches are required and our Consortium has the expertise, capacity and influence to change the paradigm of clinical TB drug development.

The overarching concept for addressing the challenge is to develop drugs and regimens with a system analogous to a car racetrack (Figure 2). The individual drugs are depicted as essential car parts. When they are ready (i.e., meaning that they have established pre-clinical, Phase 1 and Phase 2A data), they enter the pitstop, where they are prepared to be incorporated into a car, or new treatment regimen. Data from Phase 2A trials will be particularly important, providing pharmacokinetics/pharmacodynamics (PK/PD) assessments that will indicate the likely role, effective dose and duration of administration for the individual drug in any given regimen. Then, potential regimens are launched into the racetrack (which is the clinical trial platform) to participate in the race to select the best car or treatment regimen. New car parts (drugs) and cars (regimens) may enter the race when ready. The treatment regimens can experience three fates: removal, improvement, or a win. Among the latter, the best, as assessed by their efficacy and safety, will be ready for a Phase 3 clinical trial.

To be successful, the UNITE4TB Consortium requires a wide and intense collaboration across many disciplines. The UNITE4TB Consortium has brought together global leaders in the areas of TB clinical trial design, execution of Phase 2A and 2B/C trials, PK/PD and pharmacometrics, microbiological surveillance, biomarker development and analysis, artificial intelligence and machine learning, digital adherence technologies, data management, privacy and sharing, dissemination and communication, ethics, community engagement, and biobanking. Within the next 7 years, the Consortium intends to have impact on a number of critical issues within TB drug development:

- Provide new tools and understanding on how to progress TB science for the discovery and development of new clinical candidates and combinations thereof across the research and development landscape, with special emphasis on innovative clinical trial design and the development of novel biomarkers;
- Develop imaging technology, biomarkers and pharmacogenomics, diagnostics and exploit artificial intelligence for the development of new clinical candidates and combinations;
- Enable the progression of potential new, safe, efficacious, shorter and affordable treatment solutions for TB patients worldwide, with the intent to improve the quality of life and life expectancy of patients;
- Contribute to the development of a vibrant global research environment, fostering private-public collaboration across EFPIA, academia, non-governmental organisations and small- and medium-sized enterprises and strengthening the competitiveness and industrial leadership of Europe;
- Provide a legal frame and agreement on intellectual

Figure 1 Global TB drug pipeline (October 2020), with UNITE4TB EFPIA/AP drug candidates in red in the online version/grey in print. EFPIA/AP = European Federation of Pharmaceutical Industries and Associations/Associated Partners.
property terms and exploitation, as a paradigm of public and private international collaboration in the development of combination regimes;

- Implement agreements with other consortia facilitating prompt data sharing and data exploitation to accelerate TB drug regimen development;
- Contribute to the EU’s ambition of being a ‘best practice region’ for addressing antimicrobial resistance, and profit from its medical capacity to individualise and implement into medical practice combination therapies addressing MDR- and XDR-TB.

Finally, the Consortium has the ambition to advance TB science and help the global community attain the 2030 United Nations Sustainable Development Goals and WHO 2035 End TB Targets, as well as the EU and European Member States’ commitments made through the UN high-level meetings on antimicrobial resistance and TB.

The spirit of cooperation and integration of a wide number of research partners and diverse research disciplines is a reflection of a global trend and is not limited to UNITE4TB. The TB field has been successful in developing novel public-private partnerships, with early dialogue with and between regulators, policy makers and donors, critical to keeping the promises made in the Millennium Development Goals. TB has been emphasised as a health priority by the G20 heads of states conference, and the first-ever UN High-Level Meeting on Ending TB. Several related activities were initiated in 2020/21, including the TB Drug accelerator and PANTB by the Gates Foundation (https://www.europeanpharmaceuticalreview.com/news/114186/global-collaboration-formed-to-develop-novel-treatment-regimens-for-tb/) and IMI-PEARL (preparing the Phase 3 platform trial infrastructure in Europe; https://eu-pearl.eu/). The reapplication of the large US clinical trial networks (AIDS Clinical Trials Group network, https://actgnetwork.org/; and Tuberculosis Trials Consortium, https://www.cdc.gov/tb/topic/research/tbtc/) open a further opportunity to implement coordination and complementary co-operation in the field of TB drug development. The UNITE4TB research consortium will continuously update the TB com-
munity through publications in the *IJTLD* and other journals, describing its progress on this exciting journey.

M. J. BOEREE1  
C. LANGE2  
G. THWAITES3  
N. PATON4  
R. de VRUEH5  
D. BARROS6  
M. HOELSCHER7

ON BEHALF OF THE UNITE4TB CONSORTIUM*

1Lung Diseases, Radboud University Medical Center, Nijmegen, The Netherlands;  
2Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany;  
3Clinical Research Unit, Hospital for Tropical Diseases, Oxford University, Oxford, UK;  
4Global Health Portfolio, Lygature, Utrecht, The Netherlands;  
5Lygature, Utrecht, The Netherlands;  
6Global Health, GSK, Brentford, UK;  
7Department of Infectious Diseases and Tropical Medicine, Munich, Germany  
*www.unite4tb.org

Correspondence to: Martin Johan Boeree, Lung Diseases, Radboud University Medical Center, Geert Grootplein-Zuid 10, Nijmegen 6525 GA, The Netherlands. email: Martin.Boeree@radboudumc.nl

**Acknowledgements**

This publication was written on behalf of all project partners of the UNITE4TB consortium, (www.unite4tb.org). This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 101007873. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA, Deutsches Zentrum für Infektionsforschung e. V. (DZIF), and Ludwig-Maximilians-Universität München (LMU; Munich, Germany). EFPIA/AP contribute to 50% of funding, whereas the contribution of DZIF and the LMU Hospital Munich has been granted by the German Federal Ministry of Education and Research.

This communication reflects the views of the UNITE4TB Consortium and neither IMI nor the EU and EFPIA are liable for any use that may be made of the information contained herein.

Thanks to H Munnike of Lygature (Utrecht, The Netherlands) for designing the figures.

**References**

1 European Medicines Agency. Amsterdam, The Netherlands: EMA, 2020. https://www.ema.europa.eu/en/medicines/human/EPAR/sirturo
2 European Medicines Agency. Amsterdam, The Netherlands: EMA, 2021. https://www.ema.europa.eu/en/medicines/human/EPAR/deltyba
3 European Medicines Agency. Amsterdam, The Netherlands: EMA, 2021. https://www.ema.europa.eu/en/medicines/human/EPAR/pretomamid-fgk
4 FDA approves new drug for treatment-resistant forms of tuberculosis that affects the lungs. Food and Drug Administration. Washington DC, USA: FDA, 2019. https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-resistant-forms-tuberculosis-affects-lungs
5 Thwaites G, Nahid P. Triumph and tragedy of 21st century tuberculosis drug development. N Engl J Med 2020; 382: 959–960.
6 Gillespie SH, et al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med 2014; 371: 1577–1587.
7 Jindani A, et al. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med 2014; 371: 1599–1608.
8 Merle CS, et al. A four-month gatifloxacin-containing regimen for treating tuberculosis. N Engl J Med 2014; 371: 1588–1598.
9 Gler MT, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 2012; 366: 2151–2160.
10 Dorman SE, et al. Four-month rifapentine regimens with or without moxifloxacin for tuberculosis. N Engl J Med 2021; 384: 1705–1718.
11 US Food and Drug Administration. US FDA Priftin (Rifapentine) drug approval package, Oct 2000. Washington DC, USA: FDA, 2000.
12 World Health Organization. Report of the technical consultation on advances in clinical trial design for development of new TB treatments, 14–16 March 2018. WHO/CDS/TB/2018.17. Geneva, Switzerland: WHO, 2018.
13 Lienhardt C, et al. Advances in clinical trial design: Weaving tomorrow’s TB treatments. PLoS Med 2020; 17: e1003059.
14 Davies G, et al. Accelerating the transition of new tuberculosis drug combinations from Phase II to Phase III trials: New technologies and innovative designs. PLoS Med 2019; 16: e1002851.
15 Phillips PP, et al. A new trial design to accelerate tuberculosis drug development: the Phase IIC selection trial with extended post-treatment follow-up (STEP). BMC Med 2016; 14: 51.
16 Dooley KE, et al. Challenges in the clinical assessment of novel tuberculosis drugs. Adv Drug Deliv Rev 2016; 102: 116–122.